The emergence of B cell depletion strategies for the treatment of immune-mediated disorders has renewed the interest in B cell biology. B cells not only represent a potential source of autoantibodies but also modulate effector, memory, and regulatory T cell responses through antibody-independent mechanisms (1-3). Some of these mechanisms involve antigenspecific suppressive B cells (known as Breg cells), which have been identified and characterized in experimental models and in human disease (1, (4) (5) (6) (7) (8) (9) (10) .
The competency to produce and secrete interleukin-10 (IL-10) is a hallmark of Breg cells. However, more than one phenotypically distinct subpopulation of B cells seems to be able to function in a regulatory capacity (4, 11) . Breg cells have been described within both the B1 and B2 B cell lineages. In healthy individuals, ϳ10% of the immature transitional B2-phenotype peripheral B cells produce IL-10 upon CD40 engagement. These cells can limit the polarization of naive CD4 lymphocytes toward the T helper cell subtypes Th1 and Th17, and can promote the conversion of effector CD4 cells into FoxP3ϩ regulatory T cells (10, 12) . Of note, abnormalities in the number or function of Breg cells have been demonstrated in patients with different autoimmune disorders (10, (12) (13) (14) , and a positive correlation between increased numbers of transitional B cells, increased serum concentrations of IL-10, and the state of tolerance off immunosuppression has been described in kidney transplant recipients (15) .
CD5 is expressed on 80% of B cells in newborns and on 10-30% of B cells in adults (10, 16) . Most CD5ϩ B cells are naive and represent either transitional B2 B cells or T cell-independent B1 B cells. CD5 negatively regulates B cell receptor signaling (17) , induces the production of IL-10 (16), and is reported to be present in many of the phenotypes attributed to Breg cells (10, 18) . Therefore, it is conceivable that surface CD5 staining on B cells could identify a subpopulation of cells in which Breg cells are enriched. In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), increased numbers of circulatory CD25ϩCD5ϩ B cells have been linked to disease quiescence (19) . Recently, an inverse correlation between the percentage of CD5ϩ B cells and disease activity was described in a group of patients with this disease (20) . Following peripheral B cell repopulation after rituximab (RTX) administration, a higher percentage of CD5ϩ B cells (i.e., Ͼ30%) was associated with prolonged remission (20) .
The aim of this study was to analyze the kinetics of the putatively regulatory CD19ϩCD5ϩ B cell compartment in a large, well-characterized cohort of patients with AAV. In addition, we sought to explore the clinical associations of the change in the absolute and relative numbers of this cell subpopulation.
PATIENTS AND METHODS
Patient groups, treatment regimens, and definitions. The Rituximab in ANCA-Associated Vasculitis (RAVE) study was a multicenter, double-blind, placebo-controlled trial that randomized 197 patients in a 1:1 ratio to receive either RTX (375 mg/m 2 intravenously each week for 4 weeks; n ϭ 99) or cyclophosphamide (CYC) (2 mg/kg for 3-6 months) followed by azathioprine (AZA) (2 mg/kg, up to 150 mg/day) (n ϭ 98) (21) . Both groups of patients were tapered off prednisone treatment over 5.5 months, and were followed up for a total of 18 months.
Disease activity during the clinical trial was measured using the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) (maximum score 68) (22) at baseline and at 1, 2, 4, 6, 9, 12, 15, and 18 months. Patients with a BVAS/WG score of Ն1 were considered to have active disease. Complete remission was defined as a BVAS/WG score of 0, following successful completion of the prednisone taper. Severe flare was defined as a BVAS/WG score of Ն3 or the occurrence of at least one major BVAS/WG item requiring treatment with either RTX or CYC, following disease remission. Limited flare was defined as the occurrence (or worsening) of at least one minor BVAS/WG item leading to a score of Ͻ3 (21). Induction treatment failure was defined as the occurrence of a severe or limited flare that required RTX or CYC treatment within the first 6 months after initial treatment, inability to adhere to the prespecified prednisone taper due to persistent or recurrent disease activity, the occurrence of a limited flare within the first 6 months that could not be controlled by increasing the prednisone dose, or death caused by persistent disease activity.
Sample collection, cell preparation, and cell surface staining. Heparinized peripheral blood samples were obtained at baseline, 2 weeks, and 1, 2, 4, 6, 9, 12, 15, and 18 months for analysis of lymphocyte populations and subpopulations by flow cytometry. Whole blood was collected in sodium heparin vacutainers (Becton Dickinson) and shipped ambient overnight to the ITN Flow Cytometry Core (Roswell Park Cancer Institute). Using a stain-lyse method, cells from blinded samples were labeled with 5-color monoclonal antibody panels. Marker/fluorochrome combinations have been previously described (21) . Following staining, data were acquired on a FACSCanto flow cytometer (BD Biosciences). The data were analyzed using WinList software (Verity Software House).
Lymphocytes that expressed CD19 were categorized as CD19ϩ B cells (or simply B cells), and the subpopulation of CD19ϩCD5ϩ cells was identified by determining the coexpression of CD5 (categorized as CD5ϩ B cells). B cell depletion was defined as the presence of Ͻ10 CD19ϩ B cells Repeated-measures analysis of variance was performed to compare the numbers of CD5ϩ B cells between the treatment arms at each time point, and adjustment for multiple comparisons was applied using the Tukey method. Statistical associations of the explanatory variables with continuous outcomes were measured using the Mann-Whitney U test for independent observations and Wilcoxon's signed rank test for paired observations. Statistical associations of the explanatory variables with categorical outcomes were measured using Fisher's exact test and the chi-square test, as appropriate. Correlation between the CD5ϩ B cell numbers and ANCA titers at baseline was calculated using Spearman's rank test. Time-to-event comparisons were done using log-rank tests. Hazard ratios were calculated using the Cox proportional hazards method. SAS version 9.2 (SAS Institute) and the R program version 3.0.0 (http://www.r-project.org) were used for the statistical analyses. All data, as shown in Figures 1-5 , are available to the public via the ITN TrialShare system (available at https://www.itntrialshare.org/ar/figures.html).
RESULTS

Summary of the main clinical outcomes.
The clinical outcomes of the RAVE trial, as reported elsewhere (23, 24) , are summarized here. All subjects had active disease upon study enrollment (mean BVAS/WG score Ͼ8). The primary end point, complete remission at 6 months after randomization, was achieved in 64% of patients in the RTX group and 53% of patients in the CYC/AZA group (24) . At 12 months and 18 months, 48% and 39% of the patients in the RTX group, respectively, had maintained complete remission, compared with 39% and 33%, respectively, in the CYC/AZA group (23) ( Table 1) .
CD5؉ B cell kinetics in response to RTX-and CYC/AZA-based treatment regimens. We first determined the kinetics of the CD5ϩ B cell compartment in patients with AAV by treatment group (RTX n ϭ 99 and CYC/AZA n ϭ 98). Baseline characteristics were comparable between the RTX and CYC/AZA cohorts (Table 1). By 6 months after randomization, 100% of patients in the RTX arm and 80% of patients in the CYC/AZA arm achieved peripheral B cell depletion. At baseline, there was no statistically significant difference between groups in terms of the absolute numbers of CD19ϩ B cells (median 234 B cells/l in RTX-treated patients and 193 B cells/l in CYC/AZA-treated patients; P ϭ 0.13), the absolute numbers of B cells bearing the CD5 marker (median 16 CD5ϩ B cells/l in RTXtreated patients and 18 CD5ϩ B cells/l in CYC/AZAtreated patients; P ϭ 0.98), or the percentage of CD19ϩ B cells that were also CD5ϩ (median 10% CD5ϩ B cells in both groups; P ϭ 0.56) ( Table 1) .
In most patients, the absolute number of CD5ϩ B cells decreased to Ͻ5 cells/l within 8 weeks of randomization regardless of treatment allocation, and remained at that level through 6 months ( Figure 1A ). As expected, this initial decline was significantly faster and more pronounced in the RTX group. After 6 months, CD5ϩ B cell numbers progressively increased in the RTX-treated subjects, but remained low in the CYC/ AZA group. At 18 months, the median number of CD5ϩ B cells/l was 29 (interquartile range [IQR] 16-51) in patients in the RTX arm, compared with a median of 4 (IQR 2-15) in those in the CYC/AZA arm (P Ͻ 0.0001).
In contrast, the percentage of CD5ϩ B cells within the CD19ϩ B cell compartment significantly increased during remission induction, reaching a peak at 4 months in the RTX group (median CD5ϩ B cells 40%, IQR 20-67%) and 6 months in the CYC/AZA group (median CD5ϩ B cells 27%, IQR 18-36%), and gradually declined in both groups thereafter ( Figure 1B) . At 18 months, the median percentage of CD5ϩ B cells was 24% (IQR 21-28%) in the RTX group and 23% (IQR 17-29%) in the CYC/AZA group (P Ͼ 0.99).
No other baseline variables examined, including specific diagnosis (GPA versus MPA), ANCA type (PR3 versus MPO), disease presentation (new-onset versus relapse), or the presence of renal involvement upon enrollment, had any significant influence on the dynamics of the CD5ϩ B cell subpopulation in either group (data available from the corresponding author upon request). In addition, there was no statistically significant correlation between baseline percentage of CD5ϩ B cells and baseline ANCA titers (r s ϭ 0.01, P ϭ 0.89).
CD5؉ B cells as a marker of disease activity. To test the hypothesis that the relative numbers of CD5ϩ B cells are inversely correlated with disease activity, we analyzed a group of 146 patients who achieved complete remission, and divided them by treatment allocation into the categories of nonrelapsers (RTX n ϭ 52, CYC/AZA n ϭ 50) and relapsers (RTX n ϭ 24, CYC/AZA n ϭ 20). Relapse was defined as any disease exacerbation (severe or limited flare) that occurred after the achievement of complete remission. The percentages of CD5ϩ B cells were then compared within each subgroup at specific time points, including active disease at baseline, time of first complete remission, 18 months (for nonrelapsers), and active disease during a subsequent disease relapse (for relapsers) (Figure 2 ). Fifty-one patients among the original cohort of 197 did not achieve complete remission during the trial and therefore were not included in this analysis.
We found that the percentage of CD5ϩ B cells significantly increased in most patients in both treatment groups as disease activity declined toward remission, regardless of whether the subjects experienced a subsequent disease relapse. Among RTX-treated patients who were nonrelapsers, the median percentages of CD5ϩ B cells at baseline and at complete remission were 7% (IQR 3-12%) and 32% (IQR 13-57%), respectively (P Ͻ 0.0001). Among RTX-treated patients who were relapsers, the median percentages of CD5ϩ B cells at baseline and at complete remission were 12% (IQR 5-16%) and 28% (IQR 23-41%), respectively (P Ͻ 0.001). Among the CYC/AZA-treated patients, the median percentages of CD5ϩ B cells at baseline and at complete remission were 11% (IQR 8-15%) and 27% (IQR 18-36%), respectively, for nonrelapsers (P Ͻ 0.0001), and 6% (IQR 2-13%) and 26% (IQR 19-35%), respectively, for relapsers (P Ͻ 0.002). Among these 4 patient subsets-RTX nonrelapsers, RTX relapsers, 
CD5؉ B cells prior to disease relapse.
To determine whether reductions in the relative number of CD5ϩ B cells preceded disease relapse, we compared the percentage of CD5ϩ B cells by treatment group immediately before and at the time of vasculitis flare in 37 patients (RTX n ϭ 21, CYC/AZA n ϭ 16). Using, for each subject, a single measurement 20-120 days prior to disease exacerbation and a second measurement during the disease flare, the median percentage of CD5ϩ B cells was found to be 28% (IQR 21-32%) before disease exacerbation and 24% (IQR 16-34%) during the exacerbation in the RTX group (P ϭ 0.59), while the median percentage of CD5ϩ B cells was 23% (IQR 14-32%) before disease exacerbation and 19% (IQR 12-27%) during the exacerbation in the CYC/AZA group (P ϭ 0.46) (Figure 3) . Thus, we did not observe a significant decline in the percentage of CD5ϩ B cells before disease relapse.
CD5؉ B cells in relation to response to induction of remission and clinical course. To evaluate whether the initial change in the relative numbers of CD5ϩ B cells was correlated with early response to treatment, we compared the percentage of CD5ϩ B cells at baseline and during their peak levels between 4 and 6 months among patients who achieved complete remission (n ϭ 115) or failed induction treatment (n ϭ 55) by 6 months. The analysis showed no significant association between these variables (data available from the corresponding author upon request).
When divided by treatment group, longitudinal measurements of the absolute and relative CD5ϩ B cell numbers failed to discriminate between patients who maintained disease remission and those who experienced disease relapse (Figures 4A and B) . Furthermore, when individual patients were analyzed from the time of their documented complete remission forward, there was no significant difference in the trend of the CD5ϩ B cell subpopulation between patients who subsequently experienced a disease exacerbation and those whose condition stayed in remission until the end of the study (data available from the corresponding author upon request).
We also looked into the potential correlation between change in the CD5ϩ B cell fraction during induction of remission and subsequent disease severity (e.g., glomerulonephritis or alveolar hemorrhage flare). However, patients who developed poor outcomes during the study due to severe vasculitis had comparable baseline and peak percentages of CD5ϩ B cells (data available from the corresponding author upon request).
Relative numbers of CD5؉ B cells upon peripheral B cell repopulation after RTX administration as a predictor of disease relapse. In the RTX group, 77 patients achieved complete remission at any time during the 18 months of the clinical trial (Table 1) . B cell redetection (Ն10 CD19ϩ B cells/l) occurred in 69 patients after a mean period of time of 309 days, and B cell reconstitution (Ն69 CD19ϩ B cells/l) occurred in 54 patients after a mean period of time of 366 days. To study the hypothesis that the percentage of CD5ϩ B cells at the time of peripheral B cell repopulation after RTX administration is predictive of relapse-free survival (20) , we divided patients according to the CD5ϩ B cell fraction upon B cell redetection and B cell reconstitution, and performed time-to-event analyses. Glucocorticoid use was not included as a confounding factor in these comparisons because only 3 and 5 patients were still receiving prednisone at the time of B cell redetection and reconstitution, respectively. By the end of followup, B cells had not reached the threshold of redetection and reconstitution in 8 and 23 patients, respectively, and therefore these subjects were excluded from the analysis.
Based on prior reports (20), we first investigated whether the time to disease relapse was significantly longer for individuals with Ͼ30% CD5ϩ B cells at the time of B cell redetection. We found that in this group of patients, the 80th percentile of time to flare from Cox proportional hazard regression analysis showed a hazard ratio for disease flare of 1.14 (95% CI 0.49-2.64; P ϭ 0.75) in patients whose CD5ϩ B cell percentage was Ͼ30% compared with patients in whom the CD5ϩ B cell percentage was Յ30%. The wide confidence intervals for both the 80th percentile relapsefree times and the hazard ratio for disease flare indicate that there was substantial variability in the association between percentage of CD5ϩ B cells and propensity to flare. The estimated relative risk was not significantly different from 1.0 and, in fact, the point estimate was consistent with longer flare-free times for patients with lower percentages of CD5ϩ B cells at the time of B cell redetection ( Figure 5A ).
Because the estimation of percentages within a very small population of cells carries an inherent risk of being inaccurate, we also conducted analyses in patients divided on the basis of the relative number of CD5ϩ B cells at the time of B cell reconstitution. The results showed that the 80th percentile of relapse-free survival time from complete remission was 284 days (95% CI 0-369) and 181 days (95% CI 95-infinite) in patients who demonstrated Ͼ30% CD5ϩ B cells and those who demonstrated Յ30% CD5ϩ B cells at this time point, respectively. In patients whose peripheral B cell pool was reconstituted with Ͼ30% CD5ϩ B cells, the hazard ratio for disease flare was 0.9 (95% CI 0.31-2.55), which was again not significantly different from that in subjects whose peripheral B cell pool was reconstituted with Յ30% CD5ϩ B cells (P ϭ 0.84) ( Figure 5B) .
We supplemented the initial dichotomous approach with continuous variable-and categorical variable-based analyses. Nonetheless, we found no evidence of a significant or consistent trend. When we used the logarithmic transformation of the percentage of CD5ϩ B cells at the time of redetection and reconstitution as a continuous predictor, we observed no independent effect of this variable on the time to disease exacerbation (P ϭ 0.73 for redetection, P ϭ 0.12 for reconstitution).
Finally, after dividing patients based on quartiles of CD5ϩ B cell percentage upon B cell repopulation, we did not find any statistically significant difference in terms of relapse-free survival when the higher quartiles were compared with the lower quartiles. The hazard ratios for disease flare were 1.05 (95% CI 0.72-1.54; P ϭ 0.78) and 0.80 (95% CI 0.52-1.24; P ϭ 0.33) at B cell redetection and reconstitution, respectively, with no trend according to the order of the strata (Figures 5C  and D) . 
DISCUSSION
Biomarkers that predict clinical outcomes accurately and in a timely manner have been elusive in AAV. Our results, which come from the analysis of a large cohort of patients who underwent rigorous clinical monitoring and systematic blood sampling for a period of 18 months while receiving what is now considered standard of care, do not support the notion that CD19ϩCD5ϩ B cells are useful as biomarkers in current clinical practice in this disease.
We did find a statistically significant association between disease activity and the relative number of CD5ϩ B cells in the RTX treatment group. However, such an association was not observed in patients treated with CYC/AZA. In addition, we cannot completely exclude the possibility that the main driver for the changes in the CD5ϩ B cell subpopulation was the effect of immunosuppression, because the fraction of CD5ϩ B cells at the time of relapse in RTX-treated patients had declined only modestly compared with the same measurement at the time of complete remission, and most subjects who remained in complete remission also demonstrated a slow decline in their percentage of CD5ϩ B cells.
In contrast to previous reports (19, 20) , we found no significant association between the percentage of CD5ϩ B cells and disease relapse. We did not observe a decline in the percentage of these cells immediately before disease exacerbation, nor did we find any correlation between the kinetics of the CD5ϩ B cells and the relapsing phenotype. In addition, early measurements of absolute and relative CD5ϩ B cell numbers (e.g., during the first 6 months) were not significantly different between the patient subsets who achieved or failed to achieve complete remission or between patients who did and those who did not experience severe disease relapses upon further followup.
In an analysis of 19 cases, Bunch et al (20) suggested that the percentage of CD5ϩ B cells at B cell repopulation after RTX administration may be of prognostic importance in terms of estimating the duration of disease remission. Our results using 2 different cutoffs (B cell redetection, defined as 10-68 CD19ϩ B cells/l; B cell reconstitution, defined as Ն69 CD19ϩ B cells/l) showed that the relative numbers of CD5ϩ B cells were not a predictor of relapse-free survival. We observed no significant difference in the time to disease flare following complete remission among patients whose peripheral B cell pool was replenished with Ͼ30% CD5ϩ B cells as opposed to Յ30% CD5ϩ B cells. Furthermore, the division of patients by quartiles of CD5ϩ B cell percentage upon B cell repopulation failed to show any significant effect of the higher quartiles on the time to relapse, nor was there any trend according to the order of magnitude of the strata.
We did not perform intracellular staining for IL-10, labeling for other surface antigens (e.g., CD24, CD38, CD1d, CD27), or functional assays for a more accurate characterization of Breg cells. This represents an important limitation of our study. The flow cytometry assays described herein were performed in real-time throughout the RAVE trial. At the time that these studies were conceived, knowledge about Breg cell biology was relatively limited. Since then, the characterization of Breg cells and their role in experimental models and human autoimmune disease has considerably improved (1, 4, 11) . Subsequent research has shown that more than one B cell subpopulation is capable of immunoregulation, and these subpopulations exert their regulatory functions through IL-10-dependent and IL-10-independent mechanisms. high phenotype has not been reported. In addition, although CD19ϩCD24 high CD38 high Breg cells are known to be either numerically reduced or functionally deficient in patients with rheumatoid arthritis (RA) (12) and patients with systemic lupus erythematosus (SLE) (10) , data regarding the numbers or functionality of CD19ϩCD5ϩCD1d low/Ϫ B cells in RA and SLE have not been published.
An observational study found that the fractions of circulating CD19ϩCD5ϩ B cells, CD19ϩCD5ϩCD1dϩ B cells, and CD19ϩCD5ϩCD1dϩIL-10ϩ B cells are diminished in patients with early RA and increase significantly as patients enter into disease remission with immunomodulatory therapy, but no functional evaluation was performed (25) . Reduced frequencies of CD19ϩCD5ϩCD1dϩIL-10ϩ B cells and/or CD19ϩ CD24 high CD38
high B cells have also been described in patients with Crohn's disease and myasthenia gravis (13, 14) . Unfortunately, no data pertaining to the number or function of CD19ϩCD5ϩ (CD1d low/Ϫ ) B cells in these patients are available.
Breg cells in AAV have been recently studied by 3 independent groups (26) (27) (28) . However, the different phenotypic characterizations of this cell subpopulation used in those analyses, none of which included the CD5 marker, preclude comparisons with our results. Moreover, it is important to recognize that the patients in those studies were sampled on only a single occasion, while receiving a variety of immunosuppressive agents. In a study of 41 subjects, the percentage of CD19ϩIL-10ϩ B cells was significantly lower in patients compared with healthy controls, but no significant difference was detected between patients with active disease and those with inactive disease (26) . Another study of 53 subjects found a reduction in the fraction of CD19ϩ CD24 high CD38
high B cells in PR3-and MPO-ANCApositive patients with quiescent AAV and PR3-ANCApositive patients with active AAV, when compared with healthy controls (27) .
Finally, a recent study evaluated 2 putative Breg cell subsets (i.e., CD19ϩCD24 high CD38 high B cells and CD19ϩCD24 
CD38
high B cells were significantly reduced in patients in remission compared with patients whose disease was active or healthy controls. On the other hand, CD19ϩCD24 high CD27ϩ B cell numbers were significantly decreased both in patients with active disease and in patients with inactive disease compared with healthy controls. The capacity of CD19ϩ B cells to produce IL-10 and suppress the activation of monocytes, however, was not altered in these patients.
In conclusion, the sole staining for CD5 as a surrogate marker for Breg cells did not identify a subpopupation of CD19ϩ B cells with clinically meaningful value. Longitudinal studies using an expanded repertoire of surface CD markers (e.g., CD1d, CD24, CD38), intracellular staining for IL-10, and functional inhibitory assays are required to explore more thoroughly the question of Breg cells as biomarkers in AAV before any firm conclusions regarding their clinical utility are warranted.
